Kemira Oyj Stock Exchange Release July 22, 2014 at 2.30 pm (CET+1) This is a summary of the January-June 2014 Interim report. The complete January- June 2014 Interim report with tables is attached to this release and available at www.kemira.com/investors. Second quarter: * Reported revenue decreased 9% to EUR 518.2 million (569.3), due to divestments and unfavorable currency exchange rates. Revenue in local currencies, excluding acquisitions and divestments, remained flat. * Operative EBIT decreased 8% to EUR 37.0 million (40.0) with a margin of 7.1% (7.0%). Operative EBIT in local currencies, excluding acquisitions and divestments remained flat. * On July 7, Kemira signed a preliminary agreement to acquire AkzoNobel's paper chemical business. January-June: * Reported revenue decreased 7% to EUR 1,048.1 million (1,130.2), due to divestments and unfavorable currency exchange rates. Organic revenue growth reached 1%. * Operative EBIT decreased 11% to EUR 73.3 million (82.2) with a margin of 7.0% (7.3%). * Operative EBITDA decreased 6% to EUR 117.7 million (125.0) with a margin of 11.2% (11.1%). * Operative earnings per share were EUR 0.29 (0.31). * Kemira maintains its revenue outlook for 2014, but revises its profitability outlook. Kemira starts to apply operative EBITDA as its profitability metric (previously: operative EBIT) for 2014 outlook. Kemira expects operative EBITDA in 2014 to be approximately at the same level as in 2013 (previously: operative EBIT was expected to be slightly higher in 2014 as in 2013). This change from EBIT to EBITDA guidance is consistent with Kemira's earlier communicated operative EBITDA margin target and also consistent with the chemical industry practice. Detailed definition in the outlook chapter. Kemira's President and CEO Jari Rosendal: Recent divestments and unfavorable currency exchange rate fluctuations continued to impact Kemira's reported revenue. Revenue in local currencies, excluding acquisitions and divestments remained flat with modest sales volume growth. Paper and Oil & Mining sales volumes continued to grow at above-the-market rate. However, increased competition in Municipal & Industrial and our actions to improve segment's profitability continued to impact sales volumes negatively. Operative EBIT decreased 8% with somewhat higher margin. The main reasons for the decline, in addition to the unfavorable currency exchange rates, were the divestment of formic acid business as well as the increased depreciation related to the ramp up of our new manufacturing facilities in Nanjing and Dormagen, and amortization related to our recent acquisitions. We expect benefits of these investments to start to become more visible in the second half of 2014. Kemira's strategic choices presented in April 2013 remain intact. We focus on the development, application expertise, and supply of chemicals for pulp & paper, oil & gas, mining and water treatment. In order to gain a stronger position in the selected markets and to accelerate organic growth, we will invest into new, and expand our present manufacturing capacity with new and improved technologies. Going forward, we will also increase R&D investments for innovations to improve our customers processes. We are also actively evaluating inorganic growth opportunities. In the beginning of July 2014, we announced a preliminary agreement to acquire AkzoNobel's paper chemical business. It is a great fit for Kemira as it fulfills our acquisition criteria by strengthening our market position and technological capabilities. In addition, we expect to achieve significant synergies with this acquisition. The transaction is expected to close during the first quarter of 2015. Efficiency and continuous profitability improvement remain our top priorities and are the key enablers for successful strategy implementation. KEY FIGURES AND RATIOS Jan-Jun Jan-Jun Jan-Dec EUR million Apr-Jun 2014 Apr-Jun 2013 2014 2013 2013 ------------------------------------------------------------------------------- Revenue 518.2 569.3 1,048.1 1,130.2 2,229.1 ------------------------------------------------------------------------------- Operative EBITDA 60.2 61.5 117.7 125.0 251.9 ------------------------------------------------------------------------------- Operative 11.6 11.2 11.3 EBITDA, % 10.8 11.1 ------------------------------------------------------------------------------- EBITDA 34.9 41.6 112.6 102.7 141.9 ------------------------------------------------------------------------------- EBITDA, % 6.7 7.3 10.7 9.1 6.4 ------------------------------------------------------------------------------- Operative EBIT 37.0 40.0 73.3 82.2 164.2 ------------------------------------------------------------------------------- Operative EBIT, 7.1 7.0 7.4 % 7.0 7.3 ------------------------------------------------------------------------------- EBIT 10.0 13.3 64.3 52.5 42.6 ------------------------------------------------------------------------------- EBIT, % 1.9 2.3 6.1 4.6 1.9 ------------------------------------------------------------------------------- Share of profit or loss of 0.0 0.0 -1.1 associates 0.1 -1.1 ------------------------------------------------------------------------------- Financing income -8.5 -13.8 -39.0 and expenses -4.2 -28.9 ------------------------------------------------------------------------------- Profit before 1.5 50.5 2.5 tax 9.2 22.5 ------------------------------------------------------------------------------- Net profit 1.8 3.7 44.9 6.5 -25.9 ------------------------------------------------------------------------------- Earnings per 0.00 0.28 -0.21 share, EUR 0.02 0.03 ------------------------------------------------------------------------------- Operative earnings per 0.14 0.29 0.70 share, EUR 0.14 0.31 ------------------------------------------------------------------------------- Capital 1,306.6 1,306.6 1,366.5 employed* 1,505.1 1,505.1 ------------------------------------------------------------------------------- Operative ROCE* 11.9 10.4 11.9 10.4 11.9 ------------------------------------------------------------------------------- ROCE* 4.2 0.6 4.2 0.6 3.0 ------------------------------------------------------------------------------- Capital 34.0 59.6 197.5 expenditure 30.9 59.9 ------------------------------------------------------------------------------- Cash flow after investing -39.5 90.8 195.7 activities 10.5 200.4 ------------------------------------------------------------------------------- Equity ratio, % 49 49 51 at period-end 51 51 ------------------------------------------------------------------------------- Gearing, % at 41 41 41 period-end 36 36 ------------------------------------------------------------------------------- Personnel at 4,296 4,296 4,453 period-end 4,664 4,664 ------------------------------------------------------------------------------- *12-month rolling average (ROCE, % based on the reported EBIT) Definitions of key figures are available at www.kemira.com > Investors > Financial information. Comparative 2013 figures are provided in parentheses for some financial results, where appropriate. Operative EBITDA, operative EBIT, operative earnings per share and operative ROCE are excluding non-recurring items. KEMIRA'S FINANCIAL TARGETS for 2016 (unchanged) AND OUTLOOK 2014 (updated) Kemira will continue to focus on improving its profitability and reinforcing positive cash flow. The company will also continue to invest in order to secure future growth in the water quality and quantity management business. The company's financial targets for 2016 are: * revenue EUR 2.6-2.7 billion * EBITDA-% of revenue 15% * gearing level < 60%. In addition, Kemira expects its medium-term operating tax rate to be in the range of 22%-24%. The operating tax rate excludes non-recurring items and the impact of the income from associated companies. The basis for growth is the expanding market for chemicals related to water quality and quantity management and Kemira's strong expertise in this field. The need to increase operational efficiency in our customer industries creates opportunities for Kemira to develop new products and services for both current and new customers. Research and Development is a critical organic growth enabler for Kemira and it provides differentiation capabilities in the water quality and quantity management markets. Kemira will invest in innovation, technical expertise, and competencies in the targeted focus areas. Outlook (revised from the Interim Report January-March 2014) Revised outlook: In 2014, Kemira expects its revenue in local currencies and excluding acquisitionsand divestments to be slightly higher than in 2013 and its operative EBITDA to be approximately at the same level as in 2013. Previous outlook: In 2014, Kemira expects its revenue in local currencies and excluding acquisitions and divestments to be slightly higher than in 2013 and its operative EBIT to be higher than in 2013. The guidance for 2014 is defined as follows: Kemira guidance Definition ------------------------------------------------------------------- Approximately at the same level from -5% to 5% ------------------------------------------------------------------- Slightly higher/lower from 0% to 5% or from 0% to -5% ------------------------------------------------------------------- Higher/lower from 5% to 15% or from -5% to -15% ------------------------------------------------------------------- Significantly higher/lower more than 15% or less than -15% ------------------------------------------------------------------- Helsinki, July 22, 2014 Kemira Oyj Board of Directors FINANCIAL CALENDAR 2014 AND 2015 Interim Report January-September 2014 October 22, 2014 Financial results for the year 2014 February 10, 2015 Interim Report January-March 2015 April 24, 2015 Interim Report January-June 2015 July 22, 2015 Interim Report January-September 2015 October 23, 2015 Kemira Capital Markets Day will be held in London on September 9, 2014. Kemira Oyj's Annual Report 2014 will be published the week starting on February 23, 2015. The Annual General Meeting is scheduled for Monday, March 23, 2015 at 1.00 pm (CET+1). The Board of Directors of the company will convene the meeting. Press and analyst conference and conference call Kemira will arrange a press conference for analysts and the media starting at 3.30 pm (1.30 pm UK time) at Kemira House, Porkkalankatu 3, Helsinki. In the conference, Kemira's President and CEO Jari Rosendal and the CFO Petri Castrén will present the Q2 2014 results. The press conference will be held in English and will be webcasted at www.kemira.com/investors. Webcast will be available at www.kemira.com/investors also after the event. Presentation material will be available on Kemira's website at www.kemira.com/investors under Investors in English and at www.kemira.com/fi/sijoittajat in Finnish at about 3.00 pm. Conference call in connection to the press and analyst conference You can also listen to the conference live over the phone and attend the Q&A session via a conference call. In order to participate in the call, please dial ten minutes before the conference begins: FI: +358 9 817 10465 SE: +46 85 1999355 UK: +44 20 31940550 US: +1 855 2692605 No PIN code requested. For more information, please contact Kemira Oyj Tero Huovinen, VP, Investor Relations +358 10 862 1980 Kemira is a global chemicals company serving customers in water-intensive industries. We provide expertise and chemicals that improve our customers' water, energy and raw material efficiency. Our focus is on pulp & paper, oil & gas, mining and water treatment. In 2013, Kemira had annual revenue of EUR 2.2 billion and around 4,500 employees. Kemira shares are listed on the NASDAQ OMX Helsinki Ltd. www.kemira.com [HUG#1833071]
Kemira Oyj's Interim Report January-June 2014: Revenue and
Top 10 Most Recent News Articles
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations
ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market
A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...
Continue ReadingTop 5 Most Recently Viewed Articles
IONQ Achieves Record Stock Levels Amid Strong Growth Indicators
IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....
Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth
Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...
Continue Reading
Texas Instruments: Unusual Options Trends Uncovered
Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...
Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025
SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...
Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump
Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...
Continue Reading